Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal umbilical cord mesenchymal stem cells for children with spastic cerebral palsy
IRCT20110628006907N18Phase 3Completed
- Sponsor
- Royan Cord Blood Bank
- Start
- May 2023
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of allogeneic umbilical cord-derived mesenchymal stem cells in spastic cerebral palsy (2 arms), sponsored by Royan Cord Blood Bank. Primary endpoints: Gross Motor Function Measure-66 change, Gross Motor Function Classification System change and 4 more. Started May 2023; status: completed.
02
Drugs
allogeneic umbilical cord-derived mesenchymal stem cells
03
Conditions
spastic cerebral palsy
Beyond the preview
Go deeper on IRCT20110628006907N18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20110628006907N18.